iRhythm Technologies (IRTC) Projected to Announce Quarterly Earnings on Thursday

iRhythm Technologies (NASDAQ:IRTC) will likely be releasing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $219.30 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

iRhythm Technologies Stock Performance

Shares of IRTC opened at $127.13 on Wednesday. The company’s 50 day moving average price is $114.24 and its 200 day moving average price is $125.16. iRhythm Technologies has a 52 week low of $100.85 and a 52 week high of $212.00. The company has a market capitalization of $4.18 billion, a PE ratio of -147.82 and a beta of 1.30. The company has a debt-to-equity ratio of 4.03, a quick ratio of 4.98 and a current ratio of 5.17.

Insider Transactions at iRhythm Technologies

In other iRhythm Technologies news, Director Abhijit Y. Talwalkar bought 5,312 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was bought at an average cost of $10.71 per share, with a total value of $56,891.52. Following the completion of the transaction, the director directly owned 25,611 shares of the company’s stock, valued at approximately $274,293.81. The trade was a 26.17% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.98% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. RTW Investments LP bought a new stake in iRhythm Technologies in the fourth quarter worth $209,732,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in iRhythm Technologies by 45.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 829,862 shares of the company’s stock valued at $147,251,000 after buying an additional 259,800 shares in the last quarter. Millennium Management LLC lifted its position in shares of iRhythm Technologies by 197.4% in the fourth quarter. Millennium Management LLC now owns 826,376 shares of the company’s stock worth $146,632,000 after buying an additional 548,519 shares during the last quarter. Fuller & Thaler Asset Management Inc. boosted its stake in shares of iRhythm Technologies by 7.4% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 639,423 shares of the company’s stock worth $113,459,000 after acquiring an additional 44,175 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in iRhythm Technologies by 6,415.4% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 541,039 shares of the company’s stock worth $93,053,000 after purchasing an additional 532,735 shares during the last quarter.

Analyst Upgrades and Downgrades

IRTC has been the subject of a number of research reports. Wall Street Zen raised shares of iRhythm Technologies from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. BTIG Research reaffirmed a “buy” rating and issued a $185.00 price target on shares of iRhythm Technologies in a research note on Monday, June 22nd. Citigroup increased their price objective on iRhythm Technologies from $155.00 to $157.00 and gave the stock a “buy” rating in a report on Monday, May 4th. The Goldman Sachs Group reduced their price objective on iRhythm Technologies from $184.00 to $147.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Finally, Wells Fargo & Company reduced their price objective on iRhythm Technologies from $200.00 to $180.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, iRhythm Technologies presently has an average rating of “Moderate Buy” and a consensus target price of $184.71.

About iRhythm Technologies

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.